Active Peripheral Spondyloarthritis
📧 Sign up to get email alerts when something new happens for Active Peripheral Spondyloarthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2023-01-09Clinical Trial Update: Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). [Phase 3]
A Phase 3 clinical trial evaluating secukinumab for active peripheral spondyloarthritis has been withdrawn.